Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
My thoughts are near 20$ one day soon. Lots of up left on this pharm.
Hey Buzz I jumped in @ 9.69 after tracking for a while. I say at least a double from here in the short term IMO.
Thoughts as to how high this will go. I'm in at 9.5.
Boost in Biotech Funding Benefits CEL-SCI and Human Genome Sciences
The biotechnology industry has performed well in the early stages of 2012. The iShares NASDAQ Biotechnology Index is presently up nearly eight percent month-on-month as the industry continues to recover nicely from the global economic crisis. According to a recent report from Global Industry Analysts, Inc. (GIA) the improving economic conditions have led to an increase in funding for the biotechnology industry. The Paragon Report examines investing opportunities in the Biotechnology Industry and provides equity research on CEL-SCI Corporation (NYSE Amex: CVM) and Human Genome Sciences, Inc. (NASDAQ: HGSI). Access to the full company reports can be found at:
www.paragonreport.com/CVM
www.paragonreport.com/HGSI
GIA predicts the Global Biotechnology Market to Surpass US$320 Billion by 2015, as increased availability of funding for R&D, expanding use of biotechnology in agriculture and medical sciences, and favorable government initiatives are expected to drive growth in the biotechnology industry.
GIA argues that developing markets, especially India and China, will emerge as major agricultural and industrial biotechnology markets owing to rapid increase in population and income levels. "The two countries are emerging as key markets for biotech drugs due to their rich talent pool and low cost of investment," GIA stated in a press release.
The Paragon Report provides investors with an excellent first step in their due diligence by providing daily trading ideas, and consolidating the public information available on them. For more investment research on the biotechnology industry register with us free at www.paragonreport.com and get exclusive access to our numerous stock reports and industry newsletters.
CEL-SCI Corporation researches and develops drugs and vaccines. The company's lead product, Multikine, is under the Phase III clinical trial for the treatment of head and neck cancer. CEL-SCI's announced last month that its net loss available to common shareholders for the fiscal year 2011 was ($26.8) million, or ($0.13) per share, versus an income of $8.9 million, or $0.04 per share for the fiscal 2010 year.
Human Genome Sciences, Inc. operates as a biopharmaceutical company. Its principal products in development include BENLYSTA for systemic lupus erythematosus; and raxibacumab for inhalation anthrax.
The Paragon Report has not been compensated by any of the above-mentioned publicly traded companies. Paragon Report is compensated by other third party organizations for advertising services. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at http://www.paragonreport.com/disclaimer
HGSI Presentation Slides on Jan 9, 2012--Must See!
http://www.sec.gov/Archives/edgar/data/901219/000095012312000472/c26460exv99w2.htm
Those who pushed it down will bring it up!
Easy and simple!
Human Genome calls active on renewed takeover chatter 01/06 10:13 AM
Human Genome January 8 and 9 calls are active on total call option volume of 4,100 contracts (250 puts) on renewed takeover chatter. January call option implied volatility is at 81; April is at 81; above its 26-week average of 71 according to Track Data. Active call volume suggests traders positioning for price movement.
HGSI LOD 8.00
We are down to $8.00 now. I think people are scared of the law suite.
Does anyone have the articles that mention gsk interested in buying out HGSI
Or th other company that may get into a bidding war for them
This will pay for christmas
I'm in too, just with rumor of the buyout alone, HGSI can bounce back to very close to $20
I'm in. This will rally with drug and buyout rumors
HGSI below $10, its 52 weeks low level: Human Genome sinks 20% on weak lupus drug sales
Stories You Might Like
By Val Brickates Kennedy
HGSI GSK
BOSTON (MarketWatch) -- Shares of Human Genome Sciences /quotes/zigman/55662/quotes/nls/hgsi HGSI -23.24% sank 20% to $10.18 the day after the biotech firm reported weaker-than-expected sales of its new lupus drug Benlysta. According to analysts at Leerink Swann on Wednesday, Benlysta's net sales of $18.8 million for the quarter were in line with its lowered estimate of $19 million, but about 6% below the Wall Street consensus of $20.1 million. The first drug approved to treat lupus in over 50 years, industry watchers have estimated that Benlysta could be a blockbuster. As a result, Human Genome shares have been pushed markedly higher in recent weeks on rumors that it might be bought by Benlysta's co-marketer, GlaxoSmithKline PLC /quotes/zigman/146635/quotes/nls/gsk GSK +1.14% , for around $25 a share.
/quotes/zigman/55662/quotes/nls/hgsi
add Add HGSI to portfolio HGSI
Human Genome Sciences Inc.
$ 9.77
-2.96 -23.24%
Volume: 15.52M
Oct. 26, 2011 12:55p
loading...
/quotes/zigman/146635/quotes/nls/gsk
add Add GSK to portfolio GSK
GlaxoSmithKline PLC ADS
$ 44.51
+0.50 +1.14%
Volume: 2.08M
Oct. 26, 2011 12:54p
loading...
Thanks WID. That is a great presentation. I have stickyed your post so that other board readers can see it easily.
HGSI Presentation that you may need to know.
Here it is:
http://yahoo.brand.edgar-online.com/displayfilinginfo.aspx?FilingID=8138433-5044-22987&type=sect&dcn=0000950123-11-083205
Have a great day tomorrow!
HGSI on CNBC said a buyout rumor is going around. Huge volume today/ said galaxo may be a suitor for $22.00 per share or so. Lets hope so
Press Release
News for 'HGSI' - (Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Baird Conference)
ROCKVILLE, Md., Sep 02, 2011 (BUSINESS WIRE) -- Human Genome Sciences, Inc.
(NASDAQ: HGSI) announced today that its presentation at Baird's 2011 Health Care
Conference will be webcast and may be accessed at www.hgsi.com.
A member of Human Genome Sciences' senior management team will present a
corporate overview on Thursday, September 8, 2011, at 9:00 AM Eastern time.
Investors interested in listening to the live webcast should log on before the
start time in order to download any software required. The archive of the
webcast will be available for several days after the live event.
ABOUT HUMAN GENOME SCIENCES
Human Genome Sciences exists to place new therapies into the hands of those
battling serious disease.
For more information about HGS, please visit the Company's web site at
www.hgsi.com. Health professionals and patients interested in clinical trials of
HGS products may inquire via e-mail to medinfo@hgsi.com or by calling HGS at
(877) 822-8472.
HGS and Human Genome Sciences are trademarks of Human Genome Sciences, Inc.
Other trademarks referenced are the property of their respective owners.
SOURCE: Human Genome Sciences, Inc.
CON TACT:
Human Genome Sciences
Media Contacts:
Susannah Budington
Director, Corporate Public Relations
301-545-1062
or
Jerry Parrott
Vice President, Corporate Communications
301-315-2777
or
Investor Contacts:
Claudine Prowse, Ph.D.
Executive Director, Investor Relations
301-315-1785
or
Peter Vozzo
Senior Director, Investor Relations
301-251-6003
Copyright Business Wire 2011
-0-
KEYWORD: United States
North America
Maryland
New York
INDUSTRY KEYWORD: Health
Biotechnology
SUBJECT CODE: Conference
Trade Show
Webcast
News for 'HGSI' - (Shares of HGSI Down 46.5% Since Downtrend Call on Shares)
Aug 19, 2011 (SmarTrend(R) Spotlight via COMTEX) -- SmarTrend identified a
Downtrend for Human Genome Sciences (NASDAQ:HGSI) on May 16, 2011 at $26.55. In
approximately 3 months, Human Genome Sciences has returned 46.5% as of today's
recent price of $14.21.
In the past 52 weeks, shares of Human Genome Sciences have traded between a low
of $14.32 and a high of $30.48 and are now at $14.21, which is -1% above that
low price.
Human Genome Sciences is currently below its 50-day moving average of $22.02 and
below its 200-day moving average of $25.11. Look for these moving averages to
decline to confirm the company's downward momentum.
In the last five trading sessions, the 50-day MA has fallen 2.69% while the
200-day MA has slid 0.65%.
SmarTrend will continue to scan these moving averages and a number of other
proprietary indicators for any changes in momentum for shares of Human Genome
Sciences.
Write to Chip Brian at cbrian@mysmartrend.com
---------------------------------------------------------------------------------------------
SmarTrend analyzes over 5,000 securities simultaneously throughout the trading
day and provides its subscribers with trend change alerts in real time. To get a
free trial of our trading calls and maximize your trading results, please visit
http://www.mysmartrend.com
Get exclusive, actionable insight into how the market is expected to trend prior
to market open with our free morning newsletter. Sign up at:
http://www.mysmartrend.com/signup
Copyright, Comtex News Network, Inc. 2011
Put sellers active in Human Genome
Human Genome Sciences is probing long-term support, and put sellers are active before earnings.
optionMONSTER's tracking systems detected heavy activity in the August 22 contracts, which changed hands more than 5,000 times. Premiums declined from $0.68 to $0.65 as the trades crossed, with most of the volume pricing at the lows.
The put selling reflects a belief that HGSI will hold its ground or rally after reporting earnings this afternoon. (See our Education section)
The biopharmaceutical company saw a massive rally between July 2009 and April 2010 amid enthusiasm about the lupus drug Benlysta, climbing more than 1,100 percent from below $3 to over $33. Since then it's been drifting, and now is back to the lower end of its range over the last 1-1/2 years.
HGSI is down 0.56 percent to $22.96 in midday trading. It has lost 19 percent of its value in the last three months.
Revenue is expected to be $168.68 million this year, and then almost triple to $477 million in 2012. Given its huge growth prospects, some investors might consider a single quarter's worth of earnings unimportant and think that HGSI is now attractive from a long-term perspective.
The last report on April 28 missed forecasts on the bottom line as it spent money preparing to market Benlysta. Revenue, however, significantly exceeded forecasts.
HGSI 4min mainstream interview
http://www.washingtonpost.com/business/watkins-sees-human-genome-growth-on-benlysta-for-years/2011/06/27/AG30crnH_video.html
J.P. Morgan is out with its report today on Human Genome Sciences (NASDAQ: HGSI), maintaining Overweight.
In a note to clients, J.P. Morgan writes, "After market close, HGSI announced an in-licensing deal with FivePrime Therapeutics for FP-1039, an FGF fusion protein in Ph1 development for cancer. This development does not come as much of a surprise as management had been openly discussing the possibility that they would add to their oncology pipeline. If anything, we're somewhat relieved that they didn't make a bigger bet that could have diverted attention away from the pending launch of Benlysta (for lupus). We do not expect HGSI shares to react significantly one way or another given the early stage of this asset and the relatively modest price paid ($50M upfront). Maintain OW."
Source: http://www.benzinga.com/analyst-ratings/analyst-color/11/03/932700/j-p-morgan-maintains-overweight-on-human-genome-sciences-#ixzz1Gru9bwQK
sorry for the late reply.
i sold my shares on friday...
i think the base is built and now its solid than ever.
What's your thinking today?
still the labeling issue but will be interesting and should get a nice pop
sounds good - let see
hello :) i just visited yahoo hgsi board to see what other people thinking about price prediction upon approval since i have small portion here...you should go there and read...so funny!!
the funniest one was --->will open at $30 tomorrow and will end $25 tomorrow...
my prediction is different...up nicely at the open and then a bit down due to profit taking ...then the pps will go up slowly and nicely....
Have a sister with lupus. I'll pass on the news. Congrats longs.
Human Genome Sciences HGSI Stock Volume Alert! 3/1/2011
http://www.stockmarketfunding.com/Blog/Stocks/March-2011/Human-Genome-Sciences-HGSI-Stock-Volume-Alert.aspx
Video: Benlysta & Beyond Human Genome Sciences (HGSI) Exclusive Commentary - 2/27/2011
http://www.stockmarketfunding.com/Videos/Stocks/HGSI/Exclusive-Commentary-Human-Genome-Sciences-HGSI.aspx
Video: Will the FDA Approve Human Genome Sciences Benlysta for Lupus Patients?
http://www.stockmarketfunding.com/Videos/Stocks/HGSI/All-Eyes-on-Human-Genome-Sciences-Benlysta-FDA.aspx
I checked the FDA and I guess you guys have a clinical trial or I guess just another meeting with them on March 10, 2011.
WOW, that was quick, I found the anwser already and I guess it is old news to everyone here, sorry.
http://www.hgsi.com/latest/human-genome-sciences-and-glaxosmithkline-announce-fda-extension-of-benlysta-pdufa-target-date-to-march-10-2.html
Human Genome shares fall on Benlysta concerns
By Associated Press
November 17, 2010
Shares of Human Genome Sciences Inc. fell Wednesday after a Food and Drug Administration advisory panel recommended approving the company's lupus drug, but raised concerns about the treatments overall effectiveness.
The drug's effectiveness on certain patient populations could play a factor in how large a revenue driver it becomes, if it reaches the market.
THE SPARK: On Tuesday, a FDA advisory panel voted 13 to 2 in favor of approving Benlysta, but experts on the panel stressed that more effective therapies were needed because the drug will not work for all patients and that the label should be restricted accordingly. The drug did not help African-Americans in the study and that population is three times more likely to have lupus than Caucasians. The vote on effectiveness for the drug was 10 to 5 in favor.
The FDA does not have to follow the advice of its advisory panels, but often does.
THE BIG PICTURE: If approved, Benlysta will be the first new drug to treat Lupus in over 50 years. It is designed to treat flare-ups and pain caused by condition, which is a little-understood and potentially fatal ailment in which the body attacks its own tissue and organs. The disease causes skin rashes, joint pain and inflammation of the kidneys and the fibrous tissue surrounding the heart.
The FDA is scheduled to make a decision on Benlysta by Dec. 9, and company executives suggested the drug could be available in the first quarter 2011.
THE ANALYSIS: Citi analyst Dr. Yaron Werber said the label for the drug will likely have "noticeable restrictions" if approved, and he cut his 2015 sales estimate to $1.6 billion from $2.6 billion.
Werber said up to 50 percent of lupus patients could be restricted from using the drug by the label in the U.S., and 25 percent in Europe, because it will likely exclude African-Americans and patients with kidney disease.
"We did not expect that the panel will be so vocal on the need for this restriction," Werber said, in a note to investors.
SHARE ACTION: Down $1.37, or 5.3 percent, to $24.51 in trading Wednesday. The stock has traded between $20.56 and $34.49 over the last 52 weeks.
Hi closenow........started with HGSI in January of '09, once we got into the mid 20's action on the board really wained. Hope your doing well with this stock it sure has been a beauty.......
HGSI
First time on board, long time stock holder.
We might be in the early stages of a breakout above a symmetrical triangle formation. Good Sign.
It will be a great sign if we go green today and test the HOD. VERY BULLISH EVENT.
Look forward to sharing information together on this MB.
All after market.......tomorrow should be interesting......23.00/24.00 range was too tempting for me
November 16, 2010 5:39 PM ET
Human Genome Sciences and GlaxoSmithKline announce vote of FDA advisory committee to recommend approval of BENLYSTA for systemic Lupus Erythematosus Human Genome Sciences (HGSI) and GlaxoSmithKline PLC (GSK) announced that the Arthritis Advisory Committee of the U.S. Food and Drug Administration (FDA) has voted 13 to 2 to recommend that the FDA approve BENLYSTA (belimumab) for the treatment of autoantibody-positive patients with active systemic lupus erythematosus (SLE). The FDA Arthritis Advisory Committee is convened to provide the FDA with independent expert advice on a broad range of issues related to rheumatology drug products.
wow all this hype and only up 10%, woho
Why is it so Quiet in here? Especially after FDA Approval. $P$
Followers
|
21
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
636
|
Created
|
06/06/06
|
Type
|
Free
|
Moderators |
July 20, 2009 3:31 PM ET
Human Genome Sciences (NASDAQ:HGSI) is a biopharmaceutical company with a pipeline of novel protein and antibody drugs directed toward large markets that have significant unmet medical need.
HGS Home page:
HUMAN GENOME SCIENCES AND NOVOZYMES ANNOUNCE AMENDMENT TO ALBUMIN FUSION LICENSE AGREEMENT |
Rockville, Maryland and Nottingham, UK - May 7, 2009 - Human Genome Sciences, Inc. (NASDAQ: HGSI) and Novozymes Biopharma, a part of Novozymes (NASDAQ: NZYM B), today announced that they have amended an existing license agreement to allow both companies to expand application of their proprietary albumin fusion technology. Under the amended agreement, HGS and Novozymes each has the opportunity to exclusively license and/or sublicense a number of albumin fusion proteins in exchange for royalties and other consideration. No existing HGS or Novozymes products or product rights, including rights licensed to other companies, are affected by these amendments. Financial or other terms of the agreement were not disclosed. "Genetic fusion of therapeutic proteins to albumin can improve the pharmacology of the proteins, resulting in important benefits to patients," said Barry A. Labinger, Executive Vice President and Chief Commercial Officer, HGS. "For example, with certain therapeutic proteins, albumin fusion may make it possible to dose less frequently and reduce side effects associated with injections. We are pleased to work with Novozymes to broaden the application of albumin fusion technology to new classes of proteins and peptides." Thomas Videbæk, Executive Vice President, Novozymes, said, "We are delighted to expand this license agreement with HGS. We license both the fusion protein and the yeast expression systems, which have been optimised for producing albumin fusion proteins as the solution that provides an efficacious half-life in patients. Our strength lies in the fact that we focus on solutions and that is why Novozymes is an ideal partner for the pharmaceutical industry. This enables Novozymes to continue to further develop albufuse®, our proprietary albumin fusion technology, and advance our existing and new partnerships." 5/21/2009Human Genome Reports Positive Results For Long-Term Phase 2 Continuation Trial Of Benlysta In SLE Patients - Update Human Genome Sciences Reveals Positive Trial Results Of Lupus Drug, Shares Up - Update Human Genome Sciences Reveals Positive Long-Term Data For BENLYSTA In Patients With Active Systemic Lupus Erythematosus - Quick Facts Human Genome Sciences - Racing To Cure Lupus Human Genome Sciences Submits Biologics License Application For ABthrax To FDA - (RTTNews) - Thursday, (5-21-09) biotechnology company Human Genome Sciences, Inc. (HGSI: News ) announced the submission of a Biologics License Application or BLA with the U.S. Food and Drug Administration or FDA related to human monoclonal antibody drug Abthrax for the treatment of inhalation anthrax. Anthrax infection is caused by a spore-forming bacterium, Bacillus anthracis, which multiplies in the body and produces lethal toxins. The Rockville, Maryland-based company said the BLA was submitted on the results of the efficacy tests of raxibacumab carried out on rabbits and monkeys. The results exhibited a survival benefit in both rabbits and monkeys, which is needed for launching the efficacy of new drugs used to counter bioterrorism. The submission also includes the results of safety studies of raxibacumab conducted in healthy human volunteers. Raxibacumab is a first-in-class treatment for anthrax, and is being developed under a contract entered into in 2006 with the Biomedical Advanced Research and Development Authority or BARDA. In the first quarter of 2009, under the BARDA contract, HGS achieved its first product sales by initiating the delivery of 20,000 doses of raxibacumab to the U.S. Strategic National Stockpile for emergency use in the treatment of inhalation anthrax. HGS said it generated revenue of $153.8 million in raxibacumab in the first quarter, including $127.8 million in product sales. The company has now completed delivery and expects to recognize at least $8.0 million in additional raxibacumab revenue in the second quarter of 2009. Commenting on the submission, HGS' senior vice president, development and regulatory affairs, Sally Bolmer said, "Based on the results of our efficacy and safety studies, we believe raxibacumab has the potential to be an important new treatment for inhalation anthrax. In addition, the raxibacumab BLA is the first HGS has submitted, so it represents a significant milestone for our company."
RELATED STORY LINKS
Human Genome Shares Rally on Drug Trial At Wall Street Journal, 6/11/2009HGS lupus drug sustained benefits for 4 years 6/11/2009CORRECTED - CORRECTED-UPDATE 2-Human Genome says lupus drug... 6/11/2009UPDATE 3-Human Genome says lupus drug shows positive results 6/11/2009Human Genome Sciences Announces Completion of Enrollment in... 6/19/2009Human Genome Sciences to Host July 20 Conference Call to... 7/1/2009
Human Genome Sciences to Host July 20 Conference Call to Discuss Top-Line Phase 3 Results for Benlysta(TM) (Formerly Lymphostat-B(R)) in Systemic Lupus ErythematosusJuly 1, 2009 7:00 AM ET All PR Newswire news ROCKVILLE, Maryland, July 1 /PRNewswire-USNewswire/ -- Human Genome Sciences, Inc. HGSI today announced that it expects to have top-line results available on Monday, July 20, from BLISS-52, the first of two pivotal Phase 3 clinical trials of BENLYSTA(TM) (belimumab, formerly LymphoStat-B(R)) in systemic lupus erythematosus (SLE). |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |